Q2 EPS Forecast for Kymera Therapeutics Increased by Analyst

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Investment analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for shares of Kymera Therapeutics in a research report issued on Monday, June 2nd. Leerink Partnrs analyst F. Khurshid now anticipates that the company will post earnings of ($1.08) per share for the quarter, up from their prior forecast of ($1.18). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Leerink Partnrs also issued estimates for Kymera Therapeutics' Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($1.23) EPS, FY2025 earnings at ($4.25) EPS and FY2026 earnings at ($4.76) EPS.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The firm had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. During the same quarter in the previous year, the business posted ($0.69) EPS. The firm's revenue was up 114.6% compared to the same quarter last year.

Several other equities research analysts also recently weighed in on the stock. UBS Group dropped their target price on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. Stifel Nicolaus initiated coverage on shares of Kymera Therapeutics in a research report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price for the company. Morgan Stanley raised shares of Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and boosted their target price for the stock from $49.00 to $79.00 in a research report on Tuesday, June 3rd. Guggenheim reissued a "buy" rating and issued a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. Finally, B. Riley raised shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $38.00 to $60.00 in a research report on Tuesday, June 3rd. Two investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $59.82.

Kymera Therapeutics Trading Down 0.1%

KYMR stock traded down $0.04 during trading on Thursday, reaching $47.62. The stock had a trading volume of 986,878 shares, compared to its average volume of 612,728. Kymera Therapeutics has a 1-year low of $19.45 and a 1-year high of $53.27. The company has a market capitalization of $3.10 billion, a P/E ratio of -20.35 and a beta of 2.07. The firm has a fifty day moving average price of $30.25 and a 200 day moving average price of $35.66.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, CEO Nello Mainolfi sold 30,000 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $1,470,000.00. Following the completion of the transaction, the chief executive officer now directly owns 660,482 shares of the company's stock, valued at $32,363,618. The trade was a 4.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Jeffrey W. Albers sold 6,349 shares of the business's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $49.00, for a total transaction of $311,101.00. The disclosure for this sale can be found here. Insiders sold 48,349 shares of company stock valued at $2,334,301 in the last ninety days. Company insiders own 16.01% of the company's stock.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently made changes to their positions in the stock. Northern Trust Corp lifted its stake in shares of Kymera Therapeutics by 14.0% in the 4th quarter. Northern Trust Corp now owns 437,833 shares of the company's stock worth $17,614,000 after acquiring an additional 53,658 shares during the period. Ameriprise Financial Inc. acquired a new stake in shares of Kymera Therapeutics in the 4th quarter worth approximately $344,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock worth $15,577,000 after acquiring an additional 20,346 shares during the period. Millennium Management LLC lifted its stake in shares of Kymera Therapeutics by 205.0% in the 4th quarter. Millennium Management LLC now owns 115,918 shares of the company's stock worth $4,663,000 after acquiring an additional 77,912 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Kymera Therapeutics by 7.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,960 shares of the company's stock worth $1,163,000 after acquiring an additional 2,011 shares during the period.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.